• 1. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 5. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745

• Catalysts and Inorganic Chemicals Inorganic Compounds Homogeneous non-metal compounds Homogeneous other non-metal compounds

Introduction to 4-fluoro-1H-pyrrolo[2,3-b]pyridine-6-carbonitrile (CAS No. 1190313-36-0)

4-fluoro-1H-pyrrolo[2,3-b]pyridine-6-carbonitrile, with the chemical identifier CAS No. 1190313-36-0, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the pyrrolopyridine class, a scaffold that is widely recognized for its structural versatility and biological activity. The presence of a fluorine atom at the 4-position and a nitrile group at the 6-position introduces unique electronic and steric properties, making it a valuable intermediate in the synthesis of biologically active molecules.

The fluorine substituent in 4-fluoro-1H-pyrrolo[2,3-b]pyridine-6-carbonitrile plays a crucial role in modulating the pharmacokinetic and pharmacodynamic properties of derived compounds. Fluorinated aromatic systems are well-documented for their ability to enhance metabolic stability, improve binding affinity to biological targets, and influence drug distribution. In recent years, there has been a surge in research focusing on fluorinated heterocycles due to their potential in developing next-generation therapeutics. The nitrile group further contributes to the compound's reactivity, enabling diverse functionalization strategies that can be exploited in drug discovery campaigns.

Recent studies have highlighted the significance of pyrrolopyridine derivatives in medicinal chemistry. These compounds have been explored as scaffolds for kinase inhibitors, antiviral agents, and anti-inflammatory drugs. Specifically, 4-fluoro-1H-pyrrolo[2,3-b]pyridine-6-carbonitrile has been investigated for its potential applications in targeting diseases associated with aberrant signaling pathways. For instance, research has demonstrated its utility in developing inhibitors of Janus kinases (JAKs), which are implicated in various inflammatory and autoimmune disorders. The combination of the fluorine atom and the nitrile group provides a tunable platform for optimizing potency and selectivity.

In the realm of drug discovery, the synthesis of 4-fluoro-1H-pyrrolo[2,3-b]pyridine-6-carbonitrile involves multi-step organic transformations that highlight the ingenuity of synthetic chemists. The introduction of the fluorine atom typically requires sophisticated methods such as halogen exchange reactions or direct fluorination protocols, while the incorporation of the nitrile group can be achieved through cyanation reactions or oxidation of hydroxyl functionalities. These synthetic strategies not only showcase the versatility of modern organic chemistry but also underscore the importance of high-yielding and scalable processes in pharmaceutical development.

The biological activity of 4-fluoro-1H-pyrrolo[2,3-b]pyridine-6-carbonitrile has been scrutinized through both computational modeling and experimental validation. Computational studies have predicted its binding interactions with target proteins using molecular docking techniques, providing insights into potential binding modes and key interactions. Experimental validation through enzyme assays and cell-based assays has further corroborated these predictions, demonstrating its efficacy as a modulator of interest. Such integrated approaches are becoming increasingly prevalent in drug discovery pipelines, ensuring that promising candidates like this one are rigorously evaluated before advancing to clinical trials.

One notable application of 4-fluoro-1H-pyrrolo[2,3-b]pyridine-6-carbonitrile is in the development of small-molecule probes for studying protein-protein interactions (PPIs). PPIs are critical mediators of cellular signaling networks and are often implicated in disease pathogenesis. By designing molecules that disrupt or stabilize specific PPIs, researchers can gain insights into disease mechanisms and identify novel therapeutic targets. The structural features of 4-fluoro-1H-pyrrolo[2,3-b]pyridine-6-carbonitrile, particularly its ability to engage with aromatic patches on protein surfaces, make it an attractive candidate for such applications.

The future prospects for 4-fluoro-1H-pyrrolo[2,3-b]pyridine-6-carbonitrile are promising, with ongoing research aimed at expanding its utility across multiple therapeutic areas. Innovations in synthetic methodologies may enable access to novel derivatives with enhanced properties, while collaborations between academia and industry could accelerate its translation into clinical applications. As our understanding of disease biology continues to evolve, compounds like this one will play an increasingly pivotal role in developing innovative treatments that address unmet medical needs.

In conclusion,4-fluoro-1H-pyrrolo[2,3-b]pyridine-6-carbonitrile (CAS No. 1190313-36-0) represents a significant advancement in pharmaceutical chemistry. Its unique structural features and demonstrated biological activity position it as a valuable tool for drug discovery efforts targeting various diseases. As research progresses，this compound is likely to continue influencing breakthroughs in medicinal chemistry，providing new hope for patients worldwide.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)